The evolution of checkpoint blockade as a cancer therapy: What's here, what's next?

Current Opinion in Immunology

Volumn 33, Issue , 2015, Pages 23-35

  Shin, Daniel Sanghoon ^a   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BMS 986016; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD137 LIGAND; CD200 ANTIGEN; CD200 RECEPTOR; CD272 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; LYMPHOCYTE ACTIVATION GENE 3; LYMPHOCYTE ACTIVATION GENE 3 IMMUNOGLOBULIN; MONOCLONAL ANTIBODY MGA271; NIVOLUMAB; PD LIGAND 1; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN B7 H3; SAMALIZUMAB; T CELL IMMUNOGLOBULIN AND MUCIN CONTAINING PROTEIN 3; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; V DOMAIN IMMUNOGLOBULIN SUPPRESSOR T CELL ACTIVATION; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VEMURAFENIB; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BINDING AFFINITY; BREAST CARCINOMA; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EVOLUTION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; INOPERABLE CANCER; KIDNEY CARCINOMA; LIVER TOXICITY; LYMPHOCYTE ACTIVATION; MELANOMA; MELANOMA B16; METASTASIS; METASTATIC MELANOMA; MOLECULAR BIOLOGY; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; CTLA-4 ANTIGEN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84921448324     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.01.006     Document Type: Review

References (196)

1. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
2. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13:1-27.
3. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
4. Goodnow C.C. Multistep pathogenesis of autoimmune disease. Cell 2007, 130:25-35.
5. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
6. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
7. Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012, 23(Suppl. 8):viii6-viii9.
8. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
9. Schwartz R.H. T cell anergy. Annu Rev Immunol 2003, 21:305-334.
10. Callahan M.K., Wolchok J.D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013, 94:41-53.
11. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
12. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
13. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
14. Butt A.Q., Mills K.H. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014, 33:4623-4631.
15. Nirschl C.J., Drake C.G. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013, 19:4917-4924.
16. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010, 37:430-439.
17. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
18. Turnis M.E., Korman A.J., Drake C.G., Vignali D.A. Combinatorial immunotherapy: PD-1 may not be LAG-ing behind any more. Oncoimmunology 2012, 1:1172-1174.
19. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
20. Linsley P.S., Brady W., Grosmaire L., Aruffo A., Damle N.K., Ledbetter J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991, 173:721-730.
21. Brunet J.F., Denizot F., Luciani M.F., Roux-Dosseto M., Suzan M., Mattei M.G., Golstein P. A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987, 328:267-270.
22. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
23. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
24. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
25. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4:336-347.
26. Pentcheva-Hoang T., Egen J.G., Wojnoonski K., Allison J.P. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004, 21:401-413.
27. + regulatory T cell function. Science 2008, 322:271-275.
28. + T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
29. Sakaguchi S., Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T. Regulatory T cells: how do they suppress immune responses?. Int Immunol 2009, 21:1105-1111.
30. Hurwitz A.A., Yu T.F., Leach D.R., Allison J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998, 95:10067-10071.
31. Kwon E.D., Hurwitz A.A., Foster B.A., Madias C., Feldhaus A.L., Greenberg N.M., Burg M.B., Allison J.P. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997, 94:8099-8103.
32. Van Ginderachter J.A., Liu Y., Geldhof A.B., Brijs L., Thielemans K., De B.P., Raes G. B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer 2000, 87:539-547.
33. Espenschied J., Lamont J., Longmate J., Pendas S., Wang Z., Diamond D.J., Ellenhorn J.D. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003, 170:3401-3407.
34. Saha A., Chatterjee S.K. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand J Immunol 2010, 71:70-82.
35. Sutmuller R.P., van Duivenvoorde L.M., van E.A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-832.
36. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
37. van E.A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366.
38. Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007, 13:5238-5242.
39. Boasberg P., Hamid O., O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010, 37:440-449.
40. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 2010, 37:450-454.
41. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
42. Camacho L.H., Antonia S., Sosman J., Kirkwood J.M., Gajewski T.F., Redman B., Pavlov D., Bulanhagui C., Bozon V.A., Gomez-Navarro J., et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009, 27:1075-1081.
43. Kirkwood J.M., Lorigan P., Hersey P., Hauschild A., Robert C., McDermott D., Marshall M.A., Gomez-Navarro J., et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010, 16:1042-1048.
44. Ribas A., Kefford R., Marshall M.A., Punt C.J., Haanen J.B., Marmol M., Garbe C., Gogas H., Schachter J., Linette G., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31:616-622.
45. Tarhini A.A., Cherian J., Moschos S.J., Tawbi H.A., Shuai Y., Gooding W.E., Sander C., Kirkwood J.M. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012, 30:322-328.
46. McNeel D.G., Smith H.A., Eickhoff J.C., Lang J.M., Staab M.J., Wilding G., Liu G. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012, 61:1137-1147.
47. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
48. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19:813-824.
49. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
50. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
51. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8:467-477.
52. Seliger B., Marincola F.M., Ferrone S., Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008, 14:550-559.
53. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
54. Jacobs J.F., Idema A.J., Bol K.F., Nierkens S., Grauer O.M., Wesseling P., Grotenhuis J.A., Hoogerbrugge P.M., de Vries I.J., Adema G.J. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. NeuroOncology 2009, 11:394-402.
55. Okudaira K., Hokari R., Tsuzuki Y., Okada Y., Komoto S., Watanabe C., Kurihara C., Kawaguchi A., Nagao S., Azuma M., et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009, 35:741-749.
56. + T cells. Cancer Res 2004, 64:1140-1145.
57. Strome S.E., Dong H., Tamura H., Voss S.G., Flies D.B., Tamada K., Salomao D., Cheville J., Hirano F., Lin W., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63:6501-6505.
58. Iwai Y., Terawaki S., Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005, 17:133-144.
59. Zang X., Allison J.P. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007, 13:5271-5279.
60. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D.B., Lau J.S., Zhu G., Tamada K., Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
61. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
62. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., Brahmer J.R., Lawrence D.P., Atkins M.B., Powderly J.D., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
63. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
64. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
65. Ribas A., Hodi F.S., Kefford R., Hamid O., Daud A., Wolchok J.D., Hwu W.J., Gangadhar T.C., Patnaik A., Joshua A.M., et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). 2014 ASCO Annual Meeting 2014, LBA9000 (abstract).
66. Harvey R.D. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther 2014, 96:214-223.
67. Stagg J., Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol 2013, 5:169-181.
68. Schalper K.A. PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 2014, 3:e29288.
69. Segal N.H., Antonia S.J., Brahmer J.R., Maio M., Blake-Haskins A., Li X., Vasselli J., Ibrahim R.A., Lutzky J., Khleif S. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. 2014 ASCO Annual Meeting 2014, 3002 (abstract).
70. Mangsbo S.M., Sandin L.C., Anger K., Korman A.J., Loskog A., Totterman T.H. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010, 33:225-235.
71. Raval R.R., Sharabi A.B., Walker A.J., Drake C.G., Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2014, 2:14.
72. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
73. Tykodi S.S. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. OncoTargets Ther 2014, 7:1349-1359.
74. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
75. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2014.
76. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012, 366:2517-2519.
77. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., Chen L., Pardoll D.M., Topalian S.L., Anders R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20:5064-5074.
78. Marzec M., Zhang Q., Goradia A., Raghunath P.N., Liu X., Paessler M., Wang H.Y., Wysocka M., Cheng M., Ruggeri B.A., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008, 105:20852-20857.
79. Kim J., Myers A.C., Chen L., Pardoll D.M., Truong-Tran Q.A., Lane A.P., McDyer J.F., Fortuno L., Schleimer R.P. Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol 2005, 33:280-289.
80. Jiang X., Zhou J., Giobbie-Hurder A., Wargo J., Hodi F.S. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013, 19:598-609.
81. Atefi M., Avramis E., Lassen A., Wong D.J., Robert L., Foulad D., Cerniglia M., Titz B., Chodon T., Graeber T.G., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014, 20:3446-3457.
82. Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., Wunderlich J.R., Mixon A., Farid S., Dudley M.E., et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014, 124:2246-2259.
83. Robins H.S., Ericson N.G., Guenthoer J., O'Briant K.C., Tewari M., Drescher C.W., Bielas J.H. Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med 2013, 5:214ra169.
84. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., Chen S., Klein A.P., Pardoll D.M., Topalian S.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127ra37.
85. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., Manning S., Greenfield E.A., Coyle A.J., Sobel R.A., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
86. Kuchroo V.K., Umetsu D.T., DeKruyff R.H., Freeman G.J. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 2003, 3:454-462.
87. Anderson A.C., Anderson D.E. TIM-3 in autoimmunity. Curr Opin Immunol 2006, 18:665-669.
88. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252.
89. + T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
90. Gao X., Zhu Y., Li G., Huang H., Zhang G., Wang F., Sun J., Yang Q., Zhang X., Lu B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 2012, 7:e30676.
91. Yang Z.Z., Grote D.M., Ziesmer S.C., Niki T., Hirashima M., Novak A.J., Witzig T.E., Ansell S.M. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012, 122:1271-1282.
92. + T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011, 117:4501-4510.
93. Ngiow S.F., von S.B., Akiba H., Yagita H., Teng M.W., Smyth M.J. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011, 71:3540-3551.
94. Huard B., Gaulard P., Faure F., Hercend T., Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 1994, 39:213-217.
95. Triebel F., Jitsukawa S., Baixeras E., Roman-Roman S., Genevee C., Viegas-Pequignot E., Hercend T. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990, 171:1393-1405.
96. Kisielow M., Kisielow J., Capoferri-Sollami G., Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol 2005, 35:2081-2088.
97. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010, 107:7875-7880.
98. Grosso J.F., Goldberg M.V., Getnet D., Bruno T.C., Yen H.R., Pyle K.J., Hipkiss E., Vignali D.A., Pardoll D.M., Drake C.G. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009, 182:6659-6669.
99. Prigent P., El M.S., Dreano M., Triebel F. Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol 1999, 29:3867-3876.
100. Brignone C., Grygar C., Marcu M., Schakel K., Triebel F. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol 2007, 179:4202-4211.
101. Brignone C., Escudier B., Grygar C., Marcu M., Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009, 15:6225-6231.
102. Brignone C., Gutierrez M., Mefti F., Brain E., Jarcau R., Cvitkovic F., Bousetta N., Medioni J., Gligorov J., Grygar C., et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010, 8:71.
103. Goldberg M.V., Drake C.G. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011, 344:269-278.
104. Brewster A.M., Hortobagyi G.N., Broglio K.R., Kau S.W., Santa-Maria C.A., Arun B., Buzdar A.U., Booser D.J., Valero V., Bondy M., et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008, 100:1179-1183.
105. Chapoval A.I., Ni J., Lau J.S., Wilcox R.A., Flies D.B., Liu D., Dong H., Sica G.L., Zhu G., Tamada K., Chen L. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001, 2:269-274.
106. Seliger B., Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012, 61:1327-1341.
107. Sun Y., Wang Y., Zhao J., Gu M., Giscombe R., Lefvert A.K., Wang X. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006, 53:143-151.
108. Loos M., Hedderich D.M., Ottenhausen M., Giese N.A., Laschinger M., Esposito I., Kleeff J., Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009, 9:463.
109. Zang X., Sullivan P.S., Soslow R.A., Waitz R., Reuter V.E., Wilton A., Thaler H.T., Arul M., Slovin S.F., Wei J., et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010, 23:1104-1112.
110. Crispen P.L., Sheinin Y., Roth T.J., Lohse C.M., Kuntz S.M., Frigola X., Thompson R.H., Boorjian S.A., Dong H., Leibovich B.C., et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008, 14:5150-5157.
111. Boorjian S.A., Sheinin Y., Crispen P.L., Farmer S.A., Lohse C.M., Kuntz S.M., Leibovich B.C., Kwon E.D., Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008, 14:4800-4808.
112. Roth T.J., Sheinin Y., Lohse C.M., Kuntz S.M., Frigola X., Inman B.A., Krambeck A.E., McKenney M.E., Karnes R.J., Blute M.L., et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007, 67:7893-7900.
113. Suh W.K., Gajewska B.U., Okada H., Gronski M.A., Bertram E.M., Dawicki W., Duncan G.S., Bukczynski J., Plyte S., Elia A., et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003, 4:899-906.
114. Wang L., Kang F.B., Shan B.E. B7-H3-mediated tumor immunology: friend or foe?. Int J Cancer 2014, 134:2764-2771.
115. Loos M., Hedderich D.M., Friess H., Kleeff J. B7-h3 and its role in antitumor immunity. Clin Dev Immunol 2010, 2010:683875.
116. Yi K.H., Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009, 229:145-151.
117. Loo D., Alderson R.F., Chen F.Z., Huang L., Zhang W., Gorlatov S., Burke S., Ciccarone V., Li H., Yang Y., et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 2012, 18:3834-3845.
118. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H., Chapoval A.I., Flies D.B., Bajorath J., Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003, 18:849-861.
119. Prasad D.V., Richards S., Mai X.M., Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003, 18:863-873.
120. Zang X., Loke P., Kim J., Murphy K., Waitz R., Allison J.P. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003, 100:10388-10392.
121. Choi I.H., Zhu G., Sica G.L., Strome S.E., Cheville J.C., Lau J.S., Zhu Y., Flies D.B., Tamada K., Chen L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 2003, 171:4650-4654.
122. Tringler B., Liu W., Corral L., Torkko K.C., Enomoto T., Davidson S., Lucia M.S., Heinz D.E., Papkoff J., Shroyer K.R. B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006, 100:44-52.
123. Mugler K.C., Singh M., Tringler B., Torkko K.C., Liu W., Papkoff J., Shroyer K.R. B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol 2007, 15:363-370.
124. Awadallah N.S., Shroyer K.R., Langer D.A., Torkko K.C., Chen Y.K., Bentz J.S., Papkoff J., Liu W., Nash S.R., Shah R.J. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 2008, 36:200-206.
125. Zang X., Thompson R.H., Al-Ahmadie H.A., Serio A.M., Reuter V.E., Eastham J.A., Scardino P.T., Sharma P., Allison J.P. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007, 104:19458-19463.
126. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., Leibovich B.C., Blute M.L., Cheville J.C., Kwon E.D. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006, 103:10391-10396.
127. Yao Y., Wang X., Jin K., Zhu J., Wang Y., Xiong S., Mao Y., Zhou L. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J Neurooncol 2008, 89:121-129.
128. Jiang J., Zhu Y., Wu C., Shen Y., Wei W., Chen L., Zheng X., Sun J., Lu B., Zhang X. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 2010, 59:1707-1714.
129. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006, 203:871-881.
130. Kryczek I., Wei S., Zou L., Zhu G., Mottram P., Xu H., Chen L., Zou W. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006, 177:40-44.
131. Wang L., Rubinstein R., Lines J.L., Wasiuk A., Ahonen C., Guo Y., Lu L.F., Gondek D., Wang Y., Fava R.A., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2011, 208:577-592.
132. Flies D.B., Wang S., Xu H., Chen L. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol 2011, 187:1537-1541.
133. Norde W.J., Hobo W., van V., Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 2012, 120:728-736.
134. Lines J.L., Pantazi E., Mak J., Sempere L.F., Wang L., O'Connell S., Ceeraz S., Suriawinata A.A., Yan S., Ernstoff M.S., et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 2014, 74:1924-1932.
135. Le M.I., Chen W., Lines J.L., Day M., Li J., Sergent P., Noelle R.J., Wang L. VISTA regulates the development of protective antitumor immunity. Cancer Res 2014, 74:1933-1944.
136. Sakr M.A., Takino T., Domoto T., Nakano H., Wong R.W., Sasaki M., Nakanuma Y., Sato H. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci 2010, 101:2368-2374.
137. Jung K., Choi I. Emerging co-signaling networks in T cell immune regulation. Immune Netw 2013, 13:184-193.
138. Beauchemin N., Draber P., Dveksler G., Gold P., Gray-Owen S., Grunert F., Hammarstrom S., Holmes K.V., Karlsson A., Kuroki M., et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999, 252:243-249.
139. Gray-Owen S.D., Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006, 6:433-446.
140. Kuespert K., Pils S., Hauck C.R. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006, 18:565-571.
141. Gambichler T., Grothe S., Rotterdam S., Altmeyer P., Kreuter A. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions. Am J Clin Pathol 2009, 131:782-787.
142. Thies A., Moll I., Berger J., Wagener C., Brummer J., Schulze H.J., Brunner G., Schumacher U. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002, 20:2530-2536.
143. Morales V.M., Christ A., Watt S.M., Kim H.S., Johnson K.W., Utku N., Texieira A.M., Mizoguchi A., Mizoguchi E., Russell G.J., et al. Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol 1999, 163:1363-1370.
144. Markel G., Wolf D., Hanna J., Gazit R., Goldman-Wohl D., Lavy Y., Yagel S., Mandelboim O. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002, 110:943-953.
145. Markel G., Lieberman N., Katz G., Arnon T.I., Lotem M., Drize O., Blumberg R.S., Bar-Haim E., Mader R., Eisenbach L., et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002, 168:2803-2810.
146. Huang Y.H., Zhu C., Kondo Y., Anderson A.C., Gandhi A., Russell A., Dougan S.K., Petersen B.S., Melum E., Pertel T., et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015, 517:386-390.
147. Ortenberg R., Sapir Y., Raz L., Hershkovitz L., Ben A.A., Sapoznik S., Barshack I., Avivi C., Berkun Y., Besser M.J., et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther 2012, 11:1300-1310.
148. Watanabe N., Gavrieli M., Sedy J.R., Yang J., Fallarino F., Loftin S.K., Hurchla M.A., Zimmerman N., Sim J., Zang X., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003, 4:670-679.
149. Murphy T.L., Murphy K.M. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol 2010, 28:389-411.
150. Sedy J.R., Gavrieli M., Potter K.G., Hurchla M.A., Lindsley R.C., Hildner K., Scheu S., Pfeffer K., Ware C.F., Murphy T.L., et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005, 6:90-98.
151. Steinberg M.W., Cheung T.C., Ware C.F. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol Rev 2011, 244:169-187.
152. del Rio M.L., Lucas C.L., Buhler L., Rayat G., Rodriguez-Barbosa J.I. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol 2010, 87:223-235.
153. + T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008, 9:176-185.
154. Cai G., Freeman G.J. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 2009, 229:244-258.
155. M'Hidi H., Thibult M.L., Chetaille B., Rey F., Bouadallah R., Nicollas R., Olive D., Xerri L. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Clin Pathol 2009, 132:589-596.
156. Pasero C., Speiser D.E., Derre L., Olive D. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr Opin Pharmacol 2012, 12:478-485.
157. Baitsch L., Baumgaertner P., Devevre E., Raghav S.K., Legat A., Barba L., Wieckowski S., Bouzourene H., Deplancke B., Romero P., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest 2011, 121:2350-2360.
158. + T cells that can be partially reversed by vaccination. J Clin Invest 2010, 120:157-167.
159. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Olive D., Kuchroo V., Zarour H.M. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012, 72:887-896.
160. Jenmalm M.C., Cherwinski H., Bowman E.P., Phillips J.H., Sedgwick J.D. Regulation of myeloid cell function through the CD200 receptor. J Immunol 2006, 176:191-199.
161. Minas K., Liversidge J. Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?. Crit Rev Immunol 2006, 26:213-230.
162. Barclay A.N., Clark M.J., McCaughan G.W. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 1986, 51:149-157.
163. Snelgrove R.J., Goulding J., Didierlaurent A.M., Lyonga D., Vekaria S., Edwards L., Gwyer E., Sedgwick J.D., Barclay A.N., Hussell T. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008, 9:1074-1083.
164. Rygiel T.P., Rijkers E.S., de Ruiter T., Stolte E.H., van der Valk M., Rimmelzwaan G.F., Boon L., van Loon A.M., Coenjaerts F.E., Hoek R.M., et al. Lack of CD200 enhances pathological T cell responses during influenza infection. J Immunol 2009, 183:1990-1996.
165. Tonks A., Hills R., White P., Rosie B., Mills K.I., Burnett A.K., Darley R.L. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007, 21:566-568.
166. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., Moine P., Bourin P., Moos M., Corre J., et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006, 108:4194-4197.
167. Siva A., Xin H., Qin F., Oltean D., Bowdish K.S., Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008, 57:987-996.
168. Coles S.J., Wang E.C., Man S., Hills R.K., Burnett A.K., Tonks A., Darley R.L. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011, 25:792-799.
169. Gorczynski R.M., Chen Z., Diao J., Khatri I., Wong K., Yu K., Behnke J. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 2010, 123:405-415.
170. de Visser K.E. Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?. Cancer Immunol Immunother 2008, 57:1531-1539.
171. Stumpfova M., Ratner D., Desciak E.B., Eliezri Y.D., Owens D.M. The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res 2010, 70:2962-2972.
172. Rygiel T.P., Meyaard L. CD200R signaling in tumor tolerance and inflammation: a tricky balance. Curr Opin Immunol 2012, 24:233-238.
173. Joller N., Peters A., Anderson A.C., Kuchroo V.K. Immune checkpoints in central nervous system autoimmunity. Immunol Rev 2012, 248:122-139.
174. Yu X., Harden K., Gonzalez L.C., Francesco M., Chiang E., Irving B., Tom I., Ivelja S., Refino C.J., Clark H., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009, 10:48-57.
175. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., Cantoni C., Grassi J., Marcenaro S., Reymond N., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
176. Lozano E., Dominguez-Villar M., Kuchroo V., Hafler D.A. The TIGIT/CD226 axis regulates human T cell function. J Immunol 2012, 188:3869-3875.
177. Hafler J.P., Maier L.M., Cooper J.D., Plagnol V., Hinks A., Simmonds M.J., Stevens H.E., Walker N.M., Healy B., Howson J.M., et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 2009, 10:5-10.
178. Maiti A.K., Kim-Howard X., Viswanathan P., Guillen L., Qian X., Rojas-Villarraga A., Sun C., Canas C., Tobon G.J., Matsuda K., et al. Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases. Rheumatology (Oxford) 2010, 49:1239-1244.
179. Joller N., Hafler J.P., Brynedal B., Kassam N., Spoerl S., Levin S.D., Sharpe A.H., Kuchroo V.K. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011, 186:1338-1342.
180. Levin S.D., Taft D.W., Brandt C.S., Bucher C., Howard E.D., Chadwick E.M., Johnston J., Hammond A., Bontadelli K., Ardourel D., et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol 2011, 41:902-915.
181. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280.
182. Intlekofer A.M., Thompson C.B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013, 94:25-39.
183. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
184. Sznol M., Kluger H.M., Callahan M.K., Postow M.A., Gordon R.A., Segal N.H., Rizvi N.A., Lesokhin A.M., Atkins M.B., Kirkwood J.M., et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). 2014 ASCO Annual Meeting 2014, LBA9003 (abstract).
185. Duraiswamy J., Kaluza K.M., Freeman G.J., Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013, 73:3591-3603.
186. McArthur G.A., Ribas A. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 2013, 31:499-506.
187. Boni A., Cogdill A.P., Dang P., Udayakumar D., Njauw C.N., Sloss C.M., Ferrone C.R., Flaherty K.T., Lawrence D.P., Fisher D.E., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
188. Koya R.C., Mok S., Otte N., Blacketor K.J., Comin-Anduix B., Tumeh P.C., Minasyan A., Graham N.A., Graeber T.G., Chodon T., et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012, 72:3928-3937.
189. Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A., Chen J.Q., Li H.S., Watowich S.S., Yang Y., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013, 19:393-403.
190. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., Mitra D., Boni A., Newton L.P., Liu C., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19:1225-1231.
191. Ribas A., Hodi F.S., Callahan M., Konto C., Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013, 368:1365-1366.
192. Ott P.A., Henry T., Baranda S.J., Frleta D., Manches O., Bogunovic D., Bhardwaj N. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 2013, 62:811-822.
193. Dubovsky J.A., Beckwith K.A., Natarajan G., Woyach J.A., Jaglowski S., Zhong Y., Hessler J.D., Liu T.M., Chang B.Y., Larkin K.M., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122:2539-2549.
194. Vargas L., Hamasy A., Nore B.F., Smith C.I. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol 2013, 78:130-139.
195. Ali K., Soond D.R., Pineiro R., Hagemann T., Pearce W., Lim E.L., Bouabe H., Scudamore C.L., Hancox T., Maecker H., et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014, 510:407-411.
196. Kingwell K. Anticancer drugs: horizons broaden for PI3Kdelta inhibitors. Nat Rev Drug Discov 2014, 13:573.